Search

Displaying results 4671 - 4680 of 7602 in total
  1. Drug

    MG98

    go.drugbank.com/drugs/DB06544
    Experimental

    MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.

  2. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  3. Drug

    Exisulind

    go.drugbank.com/drugs/DB06246
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    ABX1100

    go.drugbank.com/drugs/DB17655
    Investigational

    It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978] … ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle.

  5. Drug

    Candesartan

    go.drugbank.com/drugs/DB13919
    Investigational

    Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of [candesartan cilexetil].

  6. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV. … In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug.

  7. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

  8. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).

  9. Drug

    Ropidoxuridine

    go.drugbank.com/drugs/DB06485
    Investigational

    Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.

  10. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.